Thursday, June 29, 2017 9:10:21 AM
"we now remain in an ideal position to complete the study's."
"One issue requiring addressing was the need to develop completely new medical devices with the capability to deliver our new signal, as the older NASA-based technology was simply too outdated. We have retained a team of highly distinguished scientists in the fields of electrical engineering, electromagnetics, and biophysics who have substantial experience in developing and evaluating electromagnetic therapeutics coupled with working in concert with regulatory bodies to bring them to market. As a result, several adjustments have been made to certain structural aspects of the study, the devices utilized to deliver the therapeutic electromagnetic field and we now remain in an ideal position to complete the study."
"Because our goal remains to evaluate our electroceuticals in a clinical setting intent on eventually bringing them to market, these adjustments were necessitated to ensure not only the most favorable data from our pre-clinical studies, but also enable us to move toward clinical trials in a faster, more efficient manner."
"In addition to the Myocardial Infarction study we have further announced the commencement of additional pre-clinical studies on Critical Limb Ischemia, Non-Alcoholic Steatohepatitis and Kidney Disease. Having been once bitten, we are not projecting a completion date for any of our studies, but plan to announce results as they become available."
"Currently, we continue to work with one group which is providing the necessary capital on a monthly basis to enable the Company to fund daily operations and the pre-clinical trials. Once we are able to show positive data, we anticipate significantly more favorable financing terms at a much higher valuation."
"While our goal to uplist has not waivered, the Company believes it remains in our best interest to pursue so after we receive positive results from our studies coupled with a binding funding commitment, minimizing dilution."
Recent ENDV News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 02/02/2024 10:23:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:30:14 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 12/29/2023 08:20:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 02:08:41 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 05:21:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 10:03:32 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 08/25/2023 11:04:33 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:16:04 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM